Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.17 (-1.53%)
NASDAQ:TCON

TRACON Pharmaceuticals - TCON Stock Forecast, Price & News

$1.50
-0.01 (-0.66%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.47
▼
$1.53
50-Day Range
$1.40
▼
$1.86
52-Week Range
$1.24
▼
$3.79
Volume
32,967 shs
Average Volume
88,732 shs
Market Capitalization
$32.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

TRACON Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
566.7% Upside
$10.00 Price Target
Short Interest
Healthy
0.69% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of TRACON Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$139,341 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.14) to ($1.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

373rd out of 1,040 stocks

Biological Products, Except Diagnostic Industry

58th out of 175 stocks

See Top Rated MarketRank™ Stocks Here
TCON stock logo

About TRACON Pharmaceuticals (NASDAQ:TCON) Stock

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Stock News Headlines

November 28, 2022 | americanbankingnews.com
TRACON Pharmaceuticals (NASDAQ:TCON) Now Covered by StockNews.com
November 22, 2022 | americanbankingnews.com
Insider Buying: TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) CEO Acquires 13,900 Shares of Stock
November 21, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals doses first patient in drug trial to treat malignant tumours
November 21, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
November 20, 2022 | americanbankingnews.com
TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com
November 14, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 31, 2022 | finance.yahoo.com
TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022
October 6, 2022 | msn.com
TRACON Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
October 6, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned
September 14, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals earns FDA fast track designation for sarcoma drug envafolimab
September 14, 2022 | seekingalpha.com
Tracon wins FDA’s fast track status for connective tissue tumor candidate
September 14, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Fast Track Designation by the FDA for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS
September 7, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 6, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals strikes $35M debt financing facility with Runway Growth Capital
September 6, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces $35 Million Non-Dilutive Debt Financing with Runway Growth Capital
August 30, 2022 | finance.yahoo.com
US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
August 29, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals announces FDA approval for CTLA-4 antibody YH001 for treating sarcoma in combination with envafolimab
August 29, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals welcomes FDA approval of IND for CTLA-4 antibody YH001 for treating sarcoma in combination with envafolimab
August 29, 2022 | finance.yahoo.com
TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer
August 29, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Announces Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line Sarcoma Patients in Combination with Envafolimab
August 10, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals ends 2Q with strong cash runway to support key trials
August 10, 2022 | finance.yahoo.com
TRACON Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 | proactiveinvestors.com
TRACON Pharmaceuticals says ENVASARC trial gets recommendation to proceed as planned
August 8, 2022 | msn.com
TRACON Seeks FDA Nod For Initial-Stage Tissue Cancer Study
See More Headlines
Receive TCON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TRACON Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TCON Company Calendar

Last Earnings
11/03/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCON
CUSIP
N/A
CIK
1394319
Web
www.traconpharma.com
Phone
(858) 550-0780
Fax
858-550-0786
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+566.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,670,000.00
Net Margins
N/A
Pretax Margin
-9,559.54%
Return on Equity
-828.53%
Return on Assets
-147.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.53
Quick Ratio
1.53

Sales & Book Value

Annual Sales
$350,000.00
Price / Sales
91.81
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.60 per share
Price / Book
2.50

Miscellaneous

Outstanding Shares
21,422,000
Free Float
20,664,000
Market Cap
$32.13 million
Optionable
Not Optionable
Beta
1.35

Key Executives

  • Dr. Charles P. Theuer M.D. (Age 58)
    Ph.D., CEO, Pres & Director
    Comp: $827.53k
  • Mr. Scott B. Brown CPA (Age 41)
    M.S., Chief Financial Officer
    Comp: $459.21k
  • Ms. Bonne Adams (Age 45)
    Exec. VP of Clinical Operations
  • Mr. Shahe Garabedian
    Sr. VP & Head of Quality Assurance
  • Dr. James L. Freddo (Age 67)
    Chief Medical Officer
  • Mr. Ya Huang
    Exec. Director of Statistical Programming
  • Dr. Brenda Marczi Pharm.D.
    Pharmd Mba, Sr. VP of Regulatory Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCON Stock - Frequently Asked Questions

Should I buy or sell TRACON Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TRACON Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TCON shares.
View TCON analyst ratings or view top-rated stocks.

What is TRACON Pharmaceuticals' stock price forecast for 2023?

1 equities research analysts have issued twelve-month target prices for TRACON Pharmaceuticals' shares. Their TCON share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 562.3% from the stock's current price.
View analysts price targets for TCON or view top-rated stocks among Wall Street analysts.

How have TCON shares performed in 2022?

TRACON Pharmaceuticals' stock was trading at $2.77 at the beginning of the year. Since then, TCON shares have decreased by 45.5% and is now trading at $1.51.
View the best growth stocks for 2022 here.

When is TRACON Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our TCON earnings forecast.

How were TRACON Pharmaceuticals' earnings last quarter?

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.06. During the same period in the previous year, the firm earned ($0.38) EPS.

What other stocks do shareholders of TRACON Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TRACON Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP) and Onconova Therapeutics (ONTX).

When did TRACON Pharmaceuticals IPO?

(TCON) raised $47 million in an initial public offering on Friday, January 30th 2015. The company issued 3,600,000 shares at a price of $12.00-$14.00 per share. Wells Fargo Securities and Stifel acted as the underwriters for the IPO and Needham & Company and Oppenheimer were co-managers.

What is TRACON Pharmaceuticals' stock symbol?

TRACON Pharmaceuticals trades on the NASDAQ under the ticker symbol "TCON."

Who are TRACON Pharmaceuticals' major shareholders?

TRACON Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Boothbay Fund Management LLC (1.21%), Two Sigma Advisers LP (0.47%) and Renaissance Technologies LLC (0.32%). Insiders that own company stock include Charles Theuer, Ikarian Capital, Llc, Mark C Wiggins, Opaleye Management Inc, Saundra L Pelletier and Scott B Brown.
View institutional ownership trends.

How do I buy shares of TRACON Pharmaceuticals?

Shares of TCON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TRACON Pharmaceuticals' stock price today?

One share of TCON stock can currently be purchased for approximately $1.51.

How much money does TRACON Pharmaceuticals make?

TRACON Pharmaceuticals (NASDAQ:TCON) has a market capitalization of $32.35 million and generates $350,000.00 in revenue each year. The biopharmaceutical company earns $-28,670,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

How can I contact TRACON Pharmaceuticals?

TRACON Pharmaceuticals' mailing address is 4350 LA JOLLA VILLAGE DRIVE SUITE 800, San Diego CA, 92122. The official website for the company is www.traconpharma.com. The biopharmaceutical company can be reached via phone at (858) 550-0780, via email at ir@traconpharma.com, or via fax at 858-550-0786.

This page (NASDAQ:TCON) was last updated on 11/28/2022 by MarketBeat.com Staff